Delivery Order SPE2DB22D2009-SPE2DB25FM1KE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count units) with a ceiling value of $4,885.54. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is scheduled for completion by August 20, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Ondansetron ODT 8 mg tablets in a 30-count package, with a ceiling value of $4,539.09 and a completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. Ondansetron is an antiemetic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units, with a ceiling value of $1,148.89. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by August 13, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ondansetron HCl 8 mg tablets (30-count units) with a ceiling value of $2,131.22. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on September 2, 2025, with performance to occur at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitive, non-set-aside delivery order carries a ceiling value of $5,838.82 under a firm fixed price arrangement, with an ultimate completion date of September 10, 2025. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) with a ceiling value of $29,329.04. This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30, with a contract ceiling value of $7,814.55. The delivery order utilizes firm fixed pricing with no set-aside designation, indicating competitive award through an open solicitation process. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania, with an ultimate completion date of September...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of $20,234.26. This firm fixed-price delivery order, with an ultimate completion date of September 10, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of $6,098.30. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by August 14, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM1KEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count units) with a ceiling value of $25,388.02. This firm fixed-price delivery order, with an ultimate completion date of September 10, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical prime vendor contract enables AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and healthcare commodities to support military healthcare programs globally. Ondansetron, an antiemetic medication commonly used in military and veteran healthcare settings for nausea prevention and management, exemplifies the company's role in fulfilling critical pharmaceutical requirements for the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.4k | 9/9/25 |